Dr. Herbst on Combination Therapies for Lung Cancer

Roy S. Herbst, MD, PhD
Published: Thursday, Jan 19, 2017



Roy S. Herbst, MD, PhD, ensign professor of Medicine, professor of Pharmacology, chief of Medical Oncology, associate director for Translational Research, Yale Cancer Center and Smilow Cancer Hospital, discusses combination therapies for patients with lung cancer.

Now that pembrolizumab (Keytruda) has moved to the first-line setting, researchers are looking at combinations involving the agent, explains Herbst. Combinations such as pembrolizumab plus the VEGF inhibitor ramucirumab (Cyramza), pembrolizumab and a CTLA-4 inhibitor, as well as pembrolizumab and a targeted agent, are all being investigated.

There are also studies looking at genetics and immunohistochemistry to determine certain characteristics of patients who respond well to treatments versus patients who do not respond.
 


Roy S. Herbst, MD, PhD, ensign professor of Medicine, professor of Pharmacology, chief of Medical Oncology, associate director for Translational Research, Yale Cancer Center and Smilow Cancer Hospital, discusses combination therapies for patients with lung cancer.

Now that pembrolizumab (Keytruda) has moved to the first-line setting, researchers are looking at combinations involving the agent, explains Herbst. Combinations such as pembrolizumab plus the VEGF inhibitor ramucirumab (Cyramza), pembrolizumab and a CTLA-4 inhibitor, as well as pembrolizumab and a targeted agent, are all being investigated.

There are also studies looking at genetics and immunohistochemistry to determine certain characteristics of patients who respond well to treatments versus patients who do not respond.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: ALK-Positive NSCLC: Emerging Strategies to Inform Sequencing, Optimize Outcomes, and Address Unmet Clinical Needs Along the Disease ContinuumAug 29, 20181.5
Community Practice Connections™: Oncogenic Tumor Board in Advanced NSCLC: Leveraging Actionable Mutations Along the Disease Continuum to Optimize Patient OutcomesAug 30, 20182.0
Publication Bottom Border
Border Publication
x